JP2022529485A - 真核細胞用の細胞培地 - Google Patents

真核細胞用の細胞培地 Download PDF

Info

Publication number
JP2022529485A
JP2022529485A JP2021562097A JP2021562097A JP2022529485A JP 2022529485 A JP2022529485 A JP 2022529485A JP 2021562097 A JP2021562097 A JP 2021562097A JP 2021562097 A JP2021562097 A JP 2021562097A JP 2022529485 A JP2022529485 A JP 2022529485A
Authority
JP
Japan
Prior art keywords
medium
cell
cell medium
cells
methylthioadenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021562097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529485A5 (https=
JPWO2020219582A5 (https=
Inventor
ウェイ シュー
ジョン チェン
キャロリン スコット
セオドア ロニー
ナサニエル ゴールデン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70681881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2022529485(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022529485A publication Critical patent/JP2022529485A/ja
Publication of JP2022529485A5 publication Critical patent/JP2022529485A5/ja
Publication of JPWO2020219582A5 publication Critical patent/JPWO2020219582A5/ja
Priority to JP2024205936A priority Critical patent/JP2025028979A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/92—Medium free of human- or animal-derived components

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021562097A 2019-04-23 2020-04-22 真核細胞用の細胞培地 Pending JP2022529485A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024205936A JP2025028979A (ja) 2019-04-23 2024-11-27 真核細胞用の細胞培地

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837263P 2019-04-23 2019-04-23
US62/837,263 2019-04-23
PCT/US2020/029370 WO2020219582A1 (en) 2019-04-23 2020-04-22 Cell culture medium for eukaryotic cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024205936A Division JP2025028979A (ja) 2019-04-23 2024-11-27 真核細胞用の細胞培地

Publications (3)

Publication Number Publication Date
JP2022529485A true JP2022529485A (ja) 2022-06-22
JP2022529485A5 JP2022529485A5 (https=) 2023-04-21
JPWO2020219582A5 JPWO2020219582A5 (https=) 2023-04-21

Family

ID=70681881

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021562097A Pending JP2022529485A (ja) 2019-04-23 2020-04-22 真核細胞用の細胞培地
JP2024205936A Pending JP2025028979A (ja) 2019-04-23 2024-11-27 真核細胞用の細胞培地

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024205936A Pending JP2025028979A (ja) 2019-04-23 2024-11-27 真核細胞用の細胞培地

Country Status (15)

Country Link
US (5) US10961500B1 (https=)
EP (1) EP3959234A1 (https=)
JP (2) JP2022529485A (https=)
KR (1) KR20220003563A (https=)
CN (1) CN113710696A (https=)
AU (1) AU2020262117B2 (https=)
BR (1) BR112021020501A2 (https=)
CA (1) CA3136827A1 (https=)
EA (1) EA202192893A1 (https=)
IL (1) IL287387A (https=)
MX (1) MX2021012649A (https=)
MY (1) MY198223A (https=)
SG (1) SG11202111252QA (https=)
WO (1) WO2020219582A1 (https=)
ZA (1) ZA202107808B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10961500B1 (en) * 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
WO2023278525A1 (en) * 2021-06-29 2023-01-05 Biomarin Pharmaceutical Inc. Cell culture feed for recombinant adeno-associated virus production in mammalian cells
CN118240749B (zh) * 2024-05-28 2024-08-06 烟台赛普生物技术有限公司 一种灌流培养基及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520014A (ja) * 1998-07-10 2002-07-09 中外製薬株式会社 動物細胞培養用無血清培地
JP2003510070A (ja) * 1999-09-28 2003-03-18 バクスター アクチェンゲゼルシャフト 細胞の無タンパク質かつ無血清の培養のための培地
JP2008529511A (ja) * 2005-02-11 2008-08-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 植物タンパク質加水分解産物を含有する血清フリーの細胞培養液におけるポリペプチドの生産
US20100221823A1 (en) * 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
JP2012503487A (ja) * 2008-09-26 2012-02-09 シェーリング コーポレイション 高力価抗体の製造
US20140274911A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2019010191A1 (en) * 2017-07-06 2019-01-10 Regeneron Pharmaceuticals, Inc. CELL CULTURE METHOD FOR PRODUCING GLYCOPROTEIN

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1312030C (en) * 1987-11-18 1992-12-29 Brian Maiorella Method to increase antibody titer
EP1482031B1 (en) * 1996-08-30 2015-10-28 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
SG106672A1 (en) 2002-03-08 2004-10-29 Asml Netherlands Bv Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
CN104059955A (zh) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
CA2805557A1 (en) * 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant high molecular weight vwf in cell culture
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
US10961500B1 (en) * 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520014A (ja) * 1998-07-10 2002-07-09 中外製薬株式会社 動物細胞培養用無血清培地
JP2003510070A (ja) * 1999-09-28 2003-03-18 バクスター アクチェンゲゼルシャフト 細胞の無タンパク質かつ無血清の培養のための培地
JP2008529511A (ja) * 2005-02-11 2008-08-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 植物タンパク質加水分解産物を含有する血清フリーの細胞培養液におけるポリペプチドの生産
US20100221823A1 (en) * 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
JP2012503487A (ja) * 2008-09-26 2012-02-09 シェーリング コーポレイション 高力価抗体の製造
US20140274911A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2019010191A1 (en) * 2017-07-06 2019-01-10 Regeneron Pharmaceuticals, Inc. CELL CULTURE METHOD FOR PRODUCING GLYCOPROTEIN

Also Published As

Publication number Publication date
JP2025028979A (ja) 2025-03-05
US11821001B2 (en) 2023-11-21
MX2021012649A (es) 2021-11-12
KR20220003563A (ko) 2022-01-10
SG11202111252QA (en) 2021-11-29
US20230114292A1 (en) 2023-04-13
MY198223A (en) 2023-08-14
ZA202107808B (en) 2024-11-27
US10961500B1 (en) 2021-03-30
EP3959234A1 (en) 2022-03-02
IL287387A (en) 2021-12-01
US20210261913A1 (en) 2021-08-26
US20210071135A1 (en) 2021-03-11
EA202192893A1 (ru) 2022-02-03
US11555176B2 (en) 2023-01-17
AU2020262117A1 (en) 2021-11-11
US20220177832A1 (en) 2022-06-09
US20240084248A1 (en) 2024-03-14
US11286460B2 (en) 2022-03-29
AU2020262117B2 (en) 2026-02-12
WO2020219582A1 (en) 2020-10-29
CN113710696A (zh) 2021-11-26
BR112021020501A2 (pt) 2021-12-07
CA3136827A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
AU2021200418B2 (en) Cell culture medium comprising small peptides
AU2021205088B2 (en) Serum-free cell culture medium
US11821001B2 (en) Cell culture medium for eukaryotic cells
KR20110060911A (ko) 고 역가 항체 생산
JP7551760B2 (ja) 哺乳動物細胞培養プロセス
EA052715B1 (ru) Среда для культивирования эукариотических клеток
JP7842737B2 (ja) 細胞培養プロセス
EA045820B1 (ru) Среда для культивирования эукариотических клеток
CA3202197A1 (en) Methods of improving protein titer in cell culture
CA3259418A1 (en) CELL CULTURE PROCESSES

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230413

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230725

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250107